SRPT - Free Report) announced that it has initiated a pivotal study — EMBARK — on its lead gene therapy candidate, SRP-9001, for the treatment of Duchenne ...
https://www.google.com/url?rct=j&sa=t&url=https://www.zacks.com/stock/news/1805530/sarepta-srpt-begins-pivotal-study-on-dmd-gene-therapy&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNGcnydJLawnS9C7vGS8myodADwfKg
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.